{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-025265","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2022-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.810923+00:00","generated_at":"2026-06-23T13:42:10.956523+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Interpace sells Pharma Services unit to Flagship for $7M; expects ~$5M annual cash flow improvement","bullets":["Sold Pharma Solutions business to Flagship Biosciences for ~$7M cash at close (plus up to $2M earnout based on revenue).","Transaction improves operating cash flow by nearly $5M annually, per CEO.","Pro forma: six-month 2022 operating loss narrows from $5.8M to $2.9M after sale.","Company becomes focused molecular diagnostics firm (PancraGEN, ThyGeNEXT, ThyraMIR, RespriDX, BarreGEN).","Ampersand and BroadOak affiliates provided equity to Flagship; Ampersand holds ~4.7M shares of Interpace common via Series B."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-025265","json":"https://secwatch.observer/filing/0001493152-22-025265.json","markdown":"https://secwatch.observer/filing/0001493152-22-025265.md","text":"https://secwatch.observer/filing/0001493152-22-025265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222025265/0001493152-22-025265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222025265/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T13:42:10.956523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}